Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:5.99.1.2 (
topoisomerase
)
9,166
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Previous studies from this laboratory indicated that microRNA-21 (miR-21) contributes to chemoresistance of glioblastoma multiforme (GBM) cells to teniposide, a type II
topoisomerase
inhibitor. We also showed that
LRRFIP1
is a target of miR-21. In this study, we found that higher baseline
LRRFIP1
expression in human GBM tissue (n=60) is associated with better prognosis upon later treatment with teniposide. Experiments in cultured U373MG cells showed enhanced toxicity of teniposide against U373MG cells transfected with a vector that resulted in
LRRFIP1
overexpression (vs. cells transfected with control vector). Experiments in nude mice demonstrated better response of
LRRFIP1
overexpressing xenografts to teniposide. These findings indicate that high baseline
LRRFIP1
expression in GBM is associated with better response to teniposide, and encourage exploring
LRRFIP1
as a target for GBM treatment.
...
PMID:Higher LRRFIP1 expression in glioblastoma multiforme is associated with better response to teniposide, a type II topoisomerase inhibitor. 2469 Jan 74